CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Versant Ventures

Sam Colella, VC

Brave New World - A Glance at the Startup Environment

Sam Colella

Sam Colella

Can you talk about your experience working with the companies in which you invest? Tell us about your investment style.


With twenty years of experience (and counting) as an operating executive, I try to use my experience to help the companies that I invest in to recruit, interview potential team members, and raise funds. I work with them in building strategies; assess them in operations such as implementation, execution, and corporate governance. Therefore, it’s a raft of responsibilities that I take on, but again it is to always support and complement the management.


Strive for excellence, and recognize the commitment you want to make to be prosperous and optimistic


I would describe my investment style as a collaborative one. I believe in teamwork, and I consider myself to be team-player. However, I have to also recognize that we are two halves; I can be a part of the team, but I have the responsibility towards the investors, employees, and even the public. My emphasis is to be a value-added investor and at the same time, work hard at trying to find situations where I can contribute.


How do you differentiate between the opportunities that you see?


We go through more than thousands of propositions a year; we only do due diligence on hundreds and end up at ten to twelve best propositions.


Also when it comes down to choosing an opportunity:


• First step: I look at the team.


• Second step: Equally important is the market. Who are the people? What are their backgrounds, experience, and expertise? Is it an attractive market, or a market available to a startup?


• Third step: I look at the innovations and invest in a breakthrough technology rather than investing in a “me too” situation


• Fourth step: I look at how much capital we need to make the company profitable and how much does it take to go public or to sell it.


• Next on my list is the business model. I prefer to evaluate whether the model makes sense, is it executable, realistic, and feasible. After having evaluated all these, the risk factors come in; I am always willing to take the risk that’s required. I do want to assess it as each situation stands on its own.


What are the key attributes you look at when evaluating a deal?


I categorize new opportunities into two buckets.


• The first bucket is what I call “Brave New World Opportunities.”


Here the risk factor is high. These situations are breakthrough technologies or ideas or concepts. If you win, you are going to win big but at the same time, you have to be willing to take that risk.


• The other bucket that I put up is opportunities that are faster, better, and cheaper ones. This is more kind of evolutionary versus revolutionary. The risk factor involved here is moderate.


How do you work with clients post investment?


I believe in being an active investor by having regular communications with the CEOs. I have adopted an open door policy through which I try to be responsive to my clients, involve in setting goals and objectives, and give reviews to them, and likewise, take reviews from them.


What would be a piece of advice that you could impart to the entrepreneur who looks to embark on a similar venture along the lines of your service?


My advice for entrepreneurs’ or people who want to start a company is to be passionate about what you are embarking on, be dedicated for being the very best to be in each situation, strive for excellence, and lastly, recognize the commitment you want to make to be prosperous and optimistic.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/brave-new-world-a-glance-at-the-startup-environment-nwid-819.html